REST - Replacing Steroids in the Transplant Ineligble
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
Newly diagnosed multiple myeloma patients ineligible for HD-ASCT will be included in the
study. All participants will receive isatuximab in combination with bortezomib, lenalidomide
and minimal dexamethasone until disease progression. The primary objective of this study is
the MRD negativity rate during and/or after first 18 cycles of study treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Helse Stavanger HF Nordic Myeloma Study Group St. Olavs Hospital